New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies.
The clinical success of the taxanes and the vinca alkaloids has sparked a major search for new drugs that perturb mitotic spindle microtubule dynamics and function, yielding a large number of promising compounds. A potential valuable strategy would be to use core microtubule-targeted drugs along with novel targeted drug therapies as they are developed, where the antitumor activity of a targeted drug can be combined with the power of low dose microtubule-targeted therapy. The goal of such combination therapy is to achieve high efficacy, reduced toxicity, and reduced emergence of drug resistance.
Wilson
L
L
Department of Molecular, Cellular, and Developmental Biology and the Neuroscience Research Institute, University of California, Santa Barbara, CA, USA. Wilson@lifesci.ucsb.edu
Jordan
M A
MA
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D006801:Humans; D008869:Microtubule-Associated Proteins / Q000187:drug effects / Q000378:metabolism; D008870:Microtubules / Q000187:drug effects* / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology; D012680:Sensitivity and Specificity; D014404:Tubulin / Q000187:drug effects* / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000972:Antineoplastic Agents, Phytogenic; D008869:Microtubule-Associated Proteins; D014404:Tubulin; D017239:Paclitaxel